恩沃利单抗治疗MSI-H/dMMR晚期实体瘤展现非凡实力（转载）

2020 ESMO ASIA︱恩沃利单抗治疗MSI-H/dMMR晚期实体瘤展现非凡实力

肿瘤资讯 肿瘤资讯 昨天

整理：肿瘤资讯

来源：肿瘤资讯

转自：良医汇-肿瘤医生APP

新型PD-L1纳米抗体恩沃利单抗（Envafolimab）治疗MSI-H/dMMR晚期实体瘤安全有效，有望成为国内首个获批MSI-H/dMMR实体瘤适应证的PD-L1单抗。

近年来，随着以PD-(L)1单抗为代表的免疫检查点抑制剂（ICI）不断上市并获批多个适应证，肿瘤免疫治疗的地位日益突出，通过有效的生物标志物筛选免疫治疗优势人群，进一步优化治疗方案成为当前研究的热点之一。2020年美国临床肿瘤学会（ASCO）年会公布的一项Ⅱ期临床研究（NCT03667170）结果显示，新型PD-L1纳米抗体恩沃利单抗（Envafolimab ）在晚期微卫星高度不稳定（MSI-H）/错配修复缺陷（dMMR）实体瘤患者中显示了持续的抗肿瘤活性和良好安全性^[1]。在2020年欧洲肿瘤内科学会亚洲峰会（ESMO ASIA）上，该研究再次公布了最新数据^[2]，让我们先睹为快。

参考文献

[1] Shen L, Li J, Deng YH, et al. Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency. 2020 ASCO, Abatract 3021.

[2] Shen L, et al. Efficacy and safety of envafolimab(KN035) in advanced tumors with mismatch repair deficiency. Abstract 607.

[3] 中国临床肿瘤学会结直肠癌专家委员会, 结直肠癌及其他相关实体瘤微卫星不稳定性检测中国专家共识[J]. 2019, 34(5): 381-389.

[4] Aaltonen LA, Peltomki P, Leach FS et al. Clues to the pathogenesis of familial colorectal cancer. Science, 1993,260: 812-816.

[5] Ionov Y, Peinado MA, Malkhosyan S, et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis[J]. Nature, 1993,363:558-561.

[6] Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon[J]. Science, 1993,260:816-819.

[7] Gelsomino F, Barbolini M, Spallanzani A, et al. The evolving role of microsatellite instability in colorectal cancer: A review[J]. Cancer Treat Rev, 2016,51: 19-26.

[8] Hause RJ, Pritchard CC, Shendure J, et al. Classification and characterization of microsatellite instability across 18 cancer types[J]. Nat Med, 2016,22:1342-1350.

[9] Overman MJ, McDermott R, Leach, JL et al. Nivolumab in patients with metastatic DNA mismatch repair deficient/microsatellite instability-high colorectal cancer (CheckMate 142): results of an open-label, multicenter, phase 2 study[J]. Lancet Oncology, 2017,18(9):1182-1191.

[10] Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med, 2015,372(26): 2509-2520.

[11] Marcus L, Lemery SJ, Keegan P, et al. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors[J]. Clinical Cancer Research, 2019,25(13):3753-3758.

[12] 江苏康宁杰瑞皮下注射PD-L1抗体KN035的临床数据将在ASCO大会发布.[EB/OL] .[2020-08-11] .

http://www.alphamabonc.com/html/news/2130.html

[13] Xu JM, Qin SK, Zhang Y, et al. Phase I Study of KN035, the first subcutaneously administered, novel fusion Anti-PD-L1 Antibody in Patients with Advanced Solid Tumors in China. 2020 ASCO Poster: 2608.

责任编辑：Linda

排版编辑：Casso